Cancer metabolism: What we can learn from proteomic analysis by mass spectrometry

Cancer Genomics and Proteomics

Volumn 9, Issue 6, 2012, Pages 373-382

  Zhou, Weidong ^a   Liotta, Lance A ^a   Petricoin, Emanuel F ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

Cancer metabolism; Mass spectrometry; Oxidative stress; Review; Warburg effect

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; AMINO ACID TRANSFER RNA LIGASE; AMINOACYL TRANSFER RNA SYNTHASE; CATHEPSIN D; CHOLESTEROL; CYTIDINE TRIPHOSPHATE; DNA; FATTY ACID; FATTY ACID SYNTHASE; FLAVINE ADENINE NUCLEOTIDE; GLUCOSE; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLUTAMINE; GLUTAMYLPROLYL TRANSFER RNA SYNTHASE; ISOCITRATE DEHYDROGENASE; LACTATE DEHYDROGENASE; LACTOSE; LYSOSOME ENZYME; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NUCLEOTIDE; PROLINE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSFER RNA; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ANALYTIC METHOD; BREAST CANCER; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; CELL METABOLISM; CHOLESTEROL SYNTHESIS; DNA DAMAGE; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GAS CHROMATOGRAPHY; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; MITOCHONDRION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PANCREAS CANCER; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; TUMOR GROWTH;

EID: 84869833726     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Molecular Biology of the Cell. Garland Science, Taylor & Francis Group, New York, 2007.
2. Jacob F and Monod J: Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol 3: 318-356, 1961.
3. Warburg O: On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
4. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007.
5. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
6. Ferreira LM: Cancer metabolism: The Warburg effect today. Exp Mol Pathol 89: 372-380, 2010.
7. Furuta E, Okuda H, Kobayashi A and Watabe K: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805: 141-152, 2010.
8. Jose C, Bellance N and Rossignol R: Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma? Biochim Biophys Acta 1807: 552-561, 2010.
9. Keijer J, Bekkenkamp-Grovenstein M, Venema D and Dommels YE: Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism. Biochim Biophys Acta 1807: 697-706, 2010.
10. Solaini G, Sgarbi G and Baracca A: Oxidative phosphorylation in cancer cells. Biochim Biophys Acta 1807: 534-542, 2010.
11. DeBerardinis RJ and Thompson CB: Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148: 1132-44, 2012.
12. Dang CV: Links between metabolism and cancer. Genes Dev 26: 877-890, 2012.
13. Griffin JL and Shockcor JP: Metabolic profiles of cancer cells. Nat Rev Cancer 4: 551-561, 2004.
14. Griffin JL and Kauppinen RA: Tumour metabolomics in animal models of human cancer. J Proteome Res 6: 498-505, 2007.
15. Muñoz-Pinedo C, El Mjiyad N and Ricci JE: Cancer metabolism: current perspectives and future directions. Cell Death Dis 3: e248, 2012.
16. Weljie AM and Jirik FR: Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. Int J Biochem Cell Biol 43: 981-989, 2011.
17. Dang CV, Hamaker M, Sun P, Le A and Gao P: Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 89: 205-212, 2011.
18. Vander Heiden MG: Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684, 2011.
19. Aebersold R and Mann M: Mass spectrometry-based proteomics. Nature 422: 198-207, 2003.
20. Domon B and Aebersold R: Mass spectrometry and protein analysis. Science 312: 212-217, 2006.
21. Cravatt BF, Simon GM and Yates JR 3rd: The biological impact of mass-spectrometry-based proteomics. Nature 450: 991-1000, 2007.
22. Nilsson T, Mann M, Aebersold R, Yates JR 3rd, Bairoch A and Bergeron JJ: Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 7: 681-685, 2010.
23. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in Cancer Biology 15: 300-308, 2005.
24. Mazurek S: Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43: 969-980, 2011.
25. Dombrauckas JD, Santarsiero BD and Mesecar AD: Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44: 9417-9429, 2005.
26. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E and Kloer HU: Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Brit J Cancer 91: 980-984, 2004.
27. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
28. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J and Cantley LC: Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79: 1118-1124, 2010.
29. Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature 452: 181-186, 2008.
30. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG and Cantley LC: Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283, 2011.
31. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J and Chen J: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2: ra73, 2009.
32. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F and Petricoin EF: Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. J Proteome Res 10: 1944-1152, 2011.
33. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F and Petricoin EF: Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 11: 554-563, 2012.
34. Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B and Ralser M: No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2: 393-400, 2011.
35. Stryer L: Biochemistry. W. H. Freeman and Company, New York, 1995.
36. Miura S: Lactic dehydrogenase isozymes of the brain. I. Electrophoretic studies on regional distribution and ontogenesis. Folia Psychiatr Neurol Jpn 20: 337-347, 1966.
37. Fan J, Hitosugi T, Chung TW, Xie J, Ge Q, Gu TL, Polakiewicz RD, Chen GZ, Boggon TJ, Lonial S, Khuri FR, Kang S and Chen J. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol 31: 4938-4950, 2011.
38. Martínez-Zaguilán R, Seftor EA, Seftor RE, Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
39. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer, Int J Radiat Oncol Biol Phys 51: 349-353, 2001.
40. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.
41. Goldman RD, Kaplan NO and Hall TC: Lactic dehydrogenase in human neoplastic tissues. Cancer Res 24: 389-99, 1964.
42. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R and Dang CV: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663, 1997.
43. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL, and Tumour and Angiogenesis Research Group: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877-885, 2003.
44. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF and Hersey P: Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol 23: 45-53, 2010.
45. Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, Aumann K, Stickeler E, Werner M, Passlick B and zur Hausen A: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 5: 22, 2010.
46. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107: 2037-2042, 2010.
47. Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434, 2006.
48. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP and Seth P: LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8: 626-635, 2009.
49. Yu Y, Deck JA, Hunsaker LA, Deck LM, Royer RE, Goldberg E and Vander Jagt DL: Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem Pharmacol 62: 81-89, 2001.
50. Granchi C, Bertini S, Macchia M and Minutolo F: Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17: 672-697, 2010.
51. Hussien R and Brooks GA: Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics 43: 255-264, 2011.
52. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X and Zhang H: Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 71: 13-18, 2011.
53. Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V and Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2: ra46, 2009.
54. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
55. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F and Petricoin EF: Mass spectrometry analysis of the post-translational modifications of á-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 9: 2929-2936, 2010.
56. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F and Petricoin EF: MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Electrophoresis 33: 1850-1854, 2012.
57. Erce MA, Pang CN, Hart-Smith G and Wilkins MR: The methylproteome and the intracellular methylation network. Proteomics 12: 564-586, 2012.
58. Wise DR and Thompson CB: Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433, 2010.
59. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S and Thompson CB: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350, 2007.
60. Erickson JW and Cerione RA: Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 1: 734-740, 2010.
61. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O and Stephanopoulos G: Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481: 380-384, 2011.
62. DeBerardinis RJ and Cheng T: Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324, 2010.
63. Levine AJ and Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344, 2010.
64. Kizaki H, Williams JC, Morris HP and Weber G: Increased cytidine 5′-triphosphate synthetase activity in rat and human tumors. Cancer Res 40: 3921-3927, 1980.
65. Ahluwalia GS, Grem JL, Hao Z and Cooney DA: Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 46: 243-271, 1990.
66. Cerini C, Kerjan P, Astier M, Gratecos D, Mirande M and Semeriva M: A component of the multisynthetase complex is a multifunctional aminoacyl-tRNA synthetase. EMBO J 10: 4267-4277, 1991.
67. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777, 2007.
68. Bertram JS: The molecular biology of cancer. Mol Aspects Med 21: 167-223, 2000.
69. Grandér D: How do mutated oncogenes and tumor suppressor genes cause cancer? Med Oncol 15: 20-26, 1998.
70. Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T and Kanematsu T: Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg 217: 138-143, 1993.
71. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC and DePinho RA: Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-670, 2012.
72. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM and Sabatini DM: Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476: 346-350, 2011.
73. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB and Mootha VK: Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336: 1040-1044, 2012.
74. Cadenas E and Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29: 222-230, 2000.
75. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M and Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
76. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Rev Drug Discovery 8: 579-591, 2009.
77. Toyokuni S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
78. Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
79. Kumar B, Koul S, Khandrika L, Meacham RB and Koul HK: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785, 2008.
80. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y and Hayashi J: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661-664, 2008.
81. Hamanaka RB and Chandel NS: Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol 21: 894-899, 2009.
82. Hamanaka RB and Chandel NS: Warburg effect and redox balance. Science 334: 1219-1220, 2011.
83. Afanas'ev I: Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis 2: 219-230, 2011.
84. Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM and Smith MA: How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic Biol Med 28: 831-834, 2000.
85. Fruehauf JP and Meyskens FL Jr.: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007.
86. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P and Brugge JS: Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113, 2009.
87. Oberley LW and Buettner GR: Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149, 1979.
88. Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D and Oberley LW: The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 63: 1297-1303, 2003.
89. Oberley TD and Oberley LW: Antioxidant enzyme levels in cancer. Histol Histopathol 12: 525-535, 1997.
90. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J and Huang P: Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 280: 39485-39492, 2005.
91. Saydam N, Kirb A, Demir O, Hazan E, Oto O, Saydam O and Güner G: Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett 119: 13-19, 1997.
92. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, Tanida O, Kohno M, Mukoyama T, Nishimuki E, Kojo H, Matsura T, Takahashi K, Osaki M, Ito H, Yodoi J, Murawaki Y and Shiota G: Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 259: 218-230, 2008.
93. Hafner Česen M, Pegan K, Spes A and Turk B: Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318: 1245-1251, 2012.
94. Lozy F and Karantza V. Autophagy and cancer cell metabolism. Semin Cell Dev Biol 23: 395-401, 2012.
95. Allison AC: Lysosomes in cancer cells. J Clin Pathol Suppl (R Coll Pathol) 7: 43-50, 1974.
96. Fehrenbacher N and Jäättelä M: Lysosomes as targets for cancer therapy. Cancer Res 65: 2993-2995, 2005.
97. Kroemer G and Jäättelä M: Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 886-897, 2005.
98. Rochefort H: Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A: 1780-1783, 1992.
99. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ and Banks RE: Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3: 1620-1632, 2003.
100. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ and Caprioli RM: Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4: 793-811, 2004.
101. Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM, Ong CN, Cheah PY, Eu KW and Hew CL: Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteomics 5: 1119-1130, 2006.
102. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H and Soga T: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69: 4918-4925, 2009.
103. Choong LY, Lim S, Chong PK, Wong CY, Shah N and Lim YP: Proteome-wide profiling of the MCF10AT breast cancer progression model. PLoS ONE 5: e11030, 2010.
104. Skvortsov S, Schäfer G, Stasyk T, Fuchsberger C, Bonn GK, Bartsch G, Klocker H and Huber LA: Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res 10: 259-268, 2011.
105. Drabovich AP, Pavlou MP, Dimitromanolakis A and Diamandis EP: Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics, Published on April 25, 2012. [Epub ahead of print].
106. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD and Comb MJ: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101, 2005.
107. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nordone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzek R, Macneill J and Ren JM: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007.
108. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y and Guan KL: Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004, 2010.